UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported):  December 15, 2006

 

BRUKER BIOSCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

 

40 Manning Road

 Billerica, MA 01821

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (978) 663-3660

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 7.01  Regulation FD Disclosure

On December 15, 2006, Bruker BioSciences Corporation issued a press release announcing that it has filed a registration statement on Form S-3 with the Securities and Exchange Commission relating to a proposed offering of an aggregate of 10,400,000 shares of its common stock, 2,200,000 of which are being offered by the Company and 8,200,000 of which are being offered by four of the Company’s major shareholders. A copy of the related press release is attached hereto as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

 

The information provided in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01  Financial Statements and Exhibits

(d) Exhibits

Exhibit
Number		Description
99.1		Bruker BioSciences Corporation press release dated December 15, 2006.

 

2

SIGNATURES

                Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		BRUKER BIOSCIENCES CORPORATION
		(Registrant)
Date: December 18, 2006		By:		/s/ Frank H. Laukien
				Frank H. Laukien, Ph.D
				Chief Executive Officer and President

 

3